1222491-53-3

Usage

Uses

Used in Pharmaceutical Research:
Tert-butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbamate is used as a protective group for amines in pharmaceutical research for enhancing the selectivity of reactions. By temporarily blocking certain functional groups, it allows for more precise and controlled synthesis of complex organic molecules, which is crucial in the development of new drugs and therapeutic agents.
Used in Agrochemical Research:
In agrochemical research, tert-butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbamate is employed as a protective group for amines to improve the selectivity of chemical reactions. This helps in the synthesis of agrochemicals with desired properties, such as increased efficacy, reduced environmental impact, and improved safety for non-target organisms.
Used in the Development of New Materials and Compounds:
Tert-butyl ((3R,6R)-rel-6-Methylpiperidin-3-yl)carbamate is utilized in the development of new materials and compounds due to its ability to act as a protective group for amines. This allows chemists to carry out selective reactions, leading to the creation of novel materials with unique properties and potential applications in various industries, such as electronics, polymers, and coatings.

Upstream product

• 323578-37-6 tert-butyl N-(6-methylpyridin-3-yl)carbamate 
• 80287-53-2 5-Amino-2-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1150618-39-5 cis/trans-tert-butyl (6-methylpiperidin-3-yl)carbamate 
• 54751-93-8 6-methyl-3-piperidinol 
• 1612786-30-7 (2R,5R)-benzyl 5-azido-2-methylpiperidine-1-carboxylate 
• 1431473-24-3 (2R,5S)-benzyl 5-hydroxy-2-methylpiperidine-1-carboxylate 
• 1612786-29-4 (2R,5S)-benzyl 2-methyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 1207853-22-2 (2R,5R)-benzyl-5-((tert-butoxycarbonyl)amino-2-methyl)piperidine-1-carboxylate 
• 1207853-72-2 benzyl (2R,5R)-5-amino-2-methyl-piperidine-1-carboxylate 
• 1207853-21-1 phenylmethyl (2S,5R)-5-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-2-methyl-1-piperidinecarboxylate 
• 1227917-61-4 (3R,6S)-6-methyl-1-{[(phenylmethyl)oxy]carbonyl}-3-piperidinecarboxylic acid 
• 1227917-62-5 (3R,6S)-3-methyl 1-(phenylmethyl) 6-methyl-1,3-piperidinedicarboxylate 
• 5470-70-2 Methyl 6-methylnicotinate 

Downstream Products

• 1207853-22-2 (2R,5R)-benzyl-5-((tert-butoxycarbonyl)amino-2-methyl)piperidine-1-carboxylate 
• 1207853-21-1 phenylmethyl (2S,5R)-5-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-2-methyl-1-piperidinecarboxylate 
• 1792180-81-4 1-[(2R,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one 
• 1792180-81-4 1-[(2S,5S)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one 
• 1222491-53-3 1,1-dimethylethyl [6-methyl-3-piperidinyl]carbamate 
• 1792180-81-4 (-) 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 
• 1792180-81-4 rac-1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 
• 1222491-53-3 tert-butyl (6-methylpiperidin-3-yl)carbamate 
• 1227917-65-8 C₂₂H₂₇FN₆O₂ 
• 1227916-43-9 C₂₂H₂₇FN₆O₂ 
• 1405129-11-4 tert-butyl ((3S,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1612786-54-5 (2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-amino-2-methylpiperidin-1-yl)methanone 
• 1612786-14-7 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)amino)isonicotinonitrile 
• 1612786-21-6 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)(methyl)amino)isonicotinonitrile 

Relevant academic research and scientific papers

Preparation method of key intermediate of JAK3 enzyme inhibitor

The invention relates to a preparation method of a key intermediate ((3R,6S)-1-benzyl-6-methyl piperidine-3-amine) of a JAK3 enzyme inhibitor, and particularly relates to a method for preparing the required intermediate by taking 6-methyl piperidine-3-amine as an initial raw material through Boc protection, catalytic hydrogenation, benzyl protection, trifluoroacetic acid Boc de-protection, salt forming and splitting, and dissociation. The salt forming and splitting method comprises the following steps: mixing a racemic mixture containing a compound enantiomer with a structure shown in the formula with a splitting reagent with definite stereo-specificity in a solvent to form a solution, wherein the splitting agent is capable of binding at least one but not all of said enantiomers to form a precipitate containing the at least one the stereo-specific form of enantiomers; and collecting and purifying the precipitate , or collecting a solution containing other enantiomers and recrystallizing the enantiomers contained in the solution. The preparation method has the advantages of cheap and easily available raw materials, mild reaction conditions, high reaction controllability and good industrial application prospect.

PYRROLO[2,3-D]PYRIMIDINE TOSYLATE SALT, CRYSTALLINE FORM THEREOF AND MANUFACTURING PROCESS AND INTERMEDIATES THERETO

The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof.

PYRROLO [2,3-d] PYRIMIDINE TOSYLATE, CRYSTALLINE FORMS THEREOF, AND PREPARATION METHOD AND INTERMEDIATE THEREOF

PROBLEM TO BE SOLVED: To provide a drug molecule in a novel or purer polymorphic form. SOLUTION: In the present invention, disclosed is a novel p-toluenesulfonate of 1-((2S,5R)-5-((7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino)-2-methyl piperidin-1-yl) prop-2-en-1-one and a crystalline polymorphic form 1 thereof, a pharmaceutical composition comprising the same, and their preparation and use. In the present invention, also disclosed is a novel phosphate of 1-((2S,5R)-5-((7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino)-2-methyl piperidin-1-yl) prop-2-en-1-one, a pharmaceutical composition comprising the same, and their preparation and use. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPOandINPIT

Process Development and Scale up of a Selective JAK3 Covalent Inhibitor PF-06651600

A scalable process for PF-06651600 (1) has been developed through successful enabling of the first generation syntheis. The synthesis highlights include the following: (1) replacement of costly PtO2 with a less expensive 5% Rh/C catalyst for a pyridine hydrogenation, (2) identification of a diasteroemeric salt crystallization to isolate the enantiomerically pure cis-isomer directly from a racemic mixture of cis/trans isomers, (3) a high yielding amidation via Schotten-Baumann conditions, and (4) critical development of a reproducible crystallization procedure for a stable crystalline salt (1·TsOH), which is suitable for long-term storage and tablet formulation. All chromatographic purifications, including two chiral SFC chromatographic separations, were eliminated. Combined with other improvements in each step of the synthesis, the overall yield was increased from 5% to 14%. Several multikilogram batches of the API have been delivered to support clinical studies.

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly s

Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists

In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile. Further structural modification led to an unexpected restoration of OX1R antagonism. Herein, these changes are discussed and a rationale for selectivity based on computational modeling is proposed.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors

High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50values of 0.024?nM and 0.095?nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50?=?28?nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

2-AMINO-3-ESTER-PYRIDYL OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or preven

PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or preventi